A Phase 1 Study of ZSP1602 in Participants With Advanced Solid Tumors
Conditions: Basal Cell Carcinoma; Medulloblastoma; Adenocarcinoma of Esophagogastric Junction; Small Cell Lung Cancer; Neuroendocrine Neoplasm; Glioblastoma Intervention: Drug: ZSP1602 Sponsor: Guangdong Zhongsheng Pharmaceutical Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Brain | Cancer | Cancer & Oncology | Carcinoma | Medulloblastoma | Neurology | Research | Study